These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16330442)

  • 21. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
    Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
    Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality.
    Matthes-Martin S; Lion T; Aberle SW; Fritsch G; Lawitschka A; Bittner B; Frommlet F; Gadner H; Peters C
    Bone Marrow Transplant; 2003 May; 31(9):803-8. PubMed ID: 12732888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
    Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
    Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
    Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
    Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus DNAemia and treatment following allogeneic stem cell transplantation with a focus on long-term outcome.
    Lindahl JK; Woxenius S; Brune M; Andersson R
    Scand J Infect Dis; 2010 Sep; 42(9):691-8. PubMed ID: 20429709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
    Song WK; Min YH; Kim YR; Lee SC
    Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies.
    Muñoz-Cobo B; Solano C; Costa E; Bravo D; Clari MÁ; Benet I; Remigia MJ; Montoro J; Navarro D
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1602-11. PubMed ID: 21871245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation.
    Mori T; Okamoto S; Watanabe R; Yajima T; Iwao Y; Yamazaki R; Nakazato T; Sato N; Iguchi T; Nagayama H; Takayama N; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2002 May; 29(9):777-82. PubMed ID: 12040476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
    Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
    Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab.
    Jain T; John J; Kotecha A; Deol A; Saliminia T; Revankar S; Chandrasekar P
    Ann Hematol; 2016 Aug; 95(8):1323-7. PubMed ID: 27225264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B; Kerridge I; Gilroy N; Huang G; Hertzberg M; Gottlieb D; Bradstock K
    Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
    Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV.
    Butt NM; Clark RE
    Bone Marrow Transplant; 2001 Mar; 27(6):615-9. PubMed ID: 11319591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.